Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials-Reference-Cited by-同舟云学术

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials

Published:2019-10 Issue: Volume:18 Page:100252
ISSN:2212-1374
Container-title:Journal of Bone Oncology
language:en
Short-container-title:Journal of Bone Oncology

Author:

Galvano Antonio,Scaturro Dalila,Badalamenti Giuseppe,Incorvaia Lorena,Rizzo Sergio,Castellana Luisa,Cusenza Stefania,Cutaia Sofia,Santini Daniele,Guadagni Fiorella,Roselli Mario,Gori Stefania,Latteri Mario Adelfio,Bazan Viviana,Giulia Letizia Mauro,Russo Antonio

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Global cancer statistics, 2002;Parkin;CA Cancer J. Clin.,2005

2. Residual risk of breast cancer recurrence 5 years after adjuvant therapy;Brewster;J. Natl. Cancer Inst.,2008

3. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results;Roehl;J. Urol.,2004

4. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease;Heidenreich;Eur. Urol.,2011

5. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Parker;Ann. Oncol.,2015

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the efficacy and safety of a proposed biosimilar QL1206 with reference denosumab in patients with bone metastasis from breast cancer: a subgroup analysis of a randomized, double-blinded phase III study;2024-06-11

2. Cancer risk in patients treated with denosumab compared with alendronate: A population-based cohort study;Bone;2024-05

3. The Impact of Non-bone Metastatic Cancer on Musculoskeletal Health;Current Osteoporosis Reports;2024-04-22

4. Research Progression in the Mechanism of Bone Metastasis and Bone-Targeted Drugs in Prostate Cancer;annals of urologic oncology;2024-02-24

5. Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate Cancer;Current Pharmaceutical Design;2023-09